Revvity has reported higher earnings and revenue for the fourth quarter of 2025, capped by stronger performance in its Diagnostics segment, and issued upbeat guidance for 2026.

 

The company posted fourth-quarter GAAP earnings of $0.87 per share, up from $0.78 a year earlier, as revenue climbed to $772 million from $729 million. Operating income from continuing operations slipped to $112 million from $119 million, reflecting margin pressure, with GAAP operating margins narrowing to 14.5% from 16.3%.

 

On an adjusted basis, earnings rose sharply. Adjusted EPS increased to $1.70 from $1.42 a year ago, while adjusted operating income grew to $229 million from $221 million. Adjusted operating margins edged down to 29.7%.

 

For the full year, Revvity reported GAAP earnings of $2.07 per share, down from $2.20 in 2024, even as revenue rose 4% to $2.86 billion. GAAP operating income increased to $357 million, and margins held essentially flat at 12.5%.

 

Adjusted full-year earnings climbed to $5.06 per share from $4.90, despite a slight decline in adjusted operating income to $773 million. Adjusted operating margins fell to 27.1% from 28.3% a year earlier.

 

“We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations,” said Prahlad Singh, President and Chief Executive Officer of Revvity. “Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come.”

 

In Life Sciences, fourth-quarter revenue rose 2% to $382 million, with organic growth flat year over year. Full-year revenue reached $1.43 billion, up 2% both reported and organically. Adjusted operating margins declined in both the quarter and the full year, reflecting continued cost and pricing pressures.

 

Diagnostics delivered stronger growth. Fourth-quarter revenue jumped 10% to $390 million, including 7% organic growth, while full-year revenue increased 5% to $1.43 billion. Despite higher sales, adjusted operating margins in the segment declined year over year.

 

Looking ahead, Revvity forecast 2026 revenue of $2.96 billion to $2.99 billion, with organic growth of 2% to 3%. The company expects adjusted earnings per share of $5.35 to $5.45, signaling confidence in continued demand recovery and portfolio execution.